HET1A cells were treated with bile acids for 6 h. For PP2 pre-treatment studies PP2 (10 uM) was added 24 h prior to co-treatment with bile acids for 6 h. For salubrinal and GSK2606414 pre-treatment studies, these compounds were added 1 h prior to co-treatment with bile acids. Cells were lysed with NP40 buffer and protein quantified using a PierceTM BCA kit (Thermo Fisher Scientific Waltham, MA USA). Equal concentrations of protein were separated by SDS-PAGE and transferred to PVDF membranes. After blocking with 5% Marvel, primary antibodies; pPERK/Total PERK/total IRE-1/pSrc/total src/pEFI2a/total EIF2α/tubulin/actin (Cell signalling Technologies Inc. Danvers, MA, USA) or pIRE-1 (Abcam, Cambridge, United Kingdom) were incubated overnight in 5% BSA/TBST. HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc. Dallas, Texas) were incubated for 1 h and detected using PierceTM ECL substrate (Thermo Fisher Scientific, Waltham, MA USA).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.